Eyevance gets global rights to Nexagon from OcuNexus
OcuNexus Therapeutics Inc. licensed Eyevance Pharmaceuticals LLC worldwide rights to develop and commercialize its ophthalmic candidate Nexagon topical gel.
- Antisense, Oligonucleotides
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.